Recent developments include clinical trial progress for PIPE-791 and PIPE-307, financial reporting, and market commentary highlighting Contineum’s pipeline and stock momentum.

• In September 2026, J&J reported that the Phase 2 MOONLIGHT-1 trial of PIPE-307 in major depressive disorder did not meet its primary efficacy endpoint; the drug was well tolerated and J&J is evaluating next steps [N1][S2].
• Contineum completed enrollment for a Phase 1b trial of PIPE-791 in chronic osteoarthritic and low back pain in Q4 2025, with topline data reported in Q2 2026 showing safety and exploratory efficacy signals [N5][S2].
• The PROPEL-IPF Phase 2 trial of PIPE-791 is ongoing with regulatory authorization in 25 countries and over 100 clinical sites opened as of October 2026 [N3][S2].
• The company reported a net loss of $18.7 million and basic and diluted EPS of -$0.49 for Q3 2026, with strong liquidity including $75.2 million cash and $169.3 million short-term investments [N8][S2].
• Market commentary in 2026 highlights Contineum as a momentum stock with analyst interest and pipeline focus, despite clinical setbacks for PIPE-307 [N3][N4][N7].

Contineum’s lead candidate PIPE-791 targets a clinically validated mechanism in IPF, a disease with limited effective treatments and significant unmet need. Positive Phase 1b PET data and ongoing Phase 2 PROPEL-IPF trial enrollment across multiple countries demonstrate clinical progress. PIPE-791’s once-daily oral dosing and favorable pharmacological properties may differentiate it from existing therapies. The company’s strong liquidity supports continued development. The partnership with Johnson & Johnson for PIPE-307 offers potential for broader pipeline value if further development is pursued despite recent Phase 2 setbacks.

PIPE-791 and PIPE-307 remain in early clinical stages with no approved products or revenues, exposing Contineum to significant clinical and regulatory risks. PIPE-307’s Phase 2 trials failed to meet primary efficacy endpoints, and J&J controls its further development, which may limit future milestone or royalty revenues. PIPE-791’s Phase 2 trial faces regulatory scrutiny, including FDA concerns about safety signals related to blood pressure, which may delay or complicate development. Clinical trial delays, failures to demonstrate efficacy or safety, and regulatory hurdles could materially harm the company’s prospects. The company’s financial sustainability depends on continued funding and successful clinical outcomes.

Contineum Therapeutics’ moat is primarily based on its proprietary small molecule drug candidates targeting validated biological pathways in diseases with high unmet need, such as IPF. PIPE-791’s differentiation lies in its pharmacological profile, including high selectivity, brain penetration, and once-daily dosing potential, which may offer advantages over existing therapies. The partnership with Johnson & Johnson for PIPE-307 provides access to significant development and commercialization resources. However, as a clinical-stage company without approved products, its competitive position depends heavily on successful clinical development and regulatory approval, which remain uncertain and subject to risks inherent in biopharmaceutical innovation.

• Clinical Development Risk: PIPE-791 and PIPE-307 are in early clinical stages with inherent risks of failure to demonstrate safety and efficacy, which could prevent regulatory approval and commercialization [S2].
• Regulatory Risk: FDA concerns about potential adverse effects related to LPA1R antagonists require additional safety data collection, which may delay trials or increase costs [S2].
• Partnership Risk: Johnson & Johnson has sole discretion over PIPE-307’s further development; discontinuation would limit Contineum’s potential milestone and royalty revenues [S2].
• Financial Risk: The company currently has no product revenues and depends on capital to fund ongoing clinical development; failure to secure funding could impair operations [S2].
• Market Competition Risk: PIPE-791 must differentiate against existing IPF therapies and other LPA1R antagonists in development to achieve commercial success [S1].

• Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies for neuroinflammation and immunology (NI&I) indications with significant unmet need [S1].
• The company has two clinical-stage, internally-discovered drug candidates: PIPE-791 and PIPE-307 [S1].
• PIPE-791 is a novel, brain-penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R), developed for idiopathic pulmonary fibrosis (IPF) and chronic pain [S1].
• PIPE-307 is a selective small-molecule inhibitor of the muscarinic type 1 receptor (M1R), developed for depression and relapsing-remitting multiple sclerosis (RRMS), in collaboration with Johnson & Johnson (J&J) [S1].
• PIPE-791 is wholly owned by Contineum, while PIPE-307 is licensed exclusively to J&J for development and commercialization [S1].
• PIPE-791 has completed Phase 1 trials including a Phase 1b PET trial confirming dose selection for a Phase 2 trial in IPF initiated in December 2025 [S1].
• Enrollment for a Phase 1b trial of PIPE-791 in chronic osteoarthritic pain and chronic low back pain was completed in Q4 2025, with topline data reported in Q2 2026 showing safety and tolerability and exploratory efficacy signals [S1][S2].
• PIPE-307's Phase 2 MOONLIGHT-1 trial for major depressive disorder (MDD) completed enrollment in June 2026 but did not meet its primary efficacy endpoint; J&J is evaluating next steps [S2].
• PIPE-307's Phase 2 VISTA trial for RRMS also did not meet primary or secondary efficacy endpoints; J&J has sole discretion on further development [S1][S2].
• PIPE-791 targets a clinically validated mechanism in IPF, a rare progressive lung disease with significant unmet medical need and limited tolerable therapies [S1].
• PIPE-791 is designed as a once-daily oral therapy with potential advantages in dosing and tolerability compared to existing IPF treatments [S1].
• PIPE-791 demonstrated potent in vitro and in vivo pharmacology, including receptor occupancy and efficacy in a rodent lung fibrosis model [S1].
• The company has deferred development of PIPE-791 for progressive multiple sclerosis and CTX-343 programs until further funding is obtained [S1].
• Contineum has received regulatory authorization to conduct the PROPEL-IPF Phase 2 trial in 25 countries with over 100 clinical sites opened as of October 2026 [S2].
• The FDA has expressed concerns about potential blood pressure-related adverse effects for LPA1R antagonists and recommended additional safety data collection; Contineum is addressing this through ongoing trials [S2].
• Contineum reported a net loss of $18.7 million and basic and diluted EPS of -$0.49 for the quarter ended September 30, 2026 [S2].
• As of September 30, 2026, Contineum held $75.2 million in cash and equivalents and $169.3 million in short-term investments, with a current ratio of 31.11 and cash ratio of 30.45, indicating strong liquidity [S2].
• The company currently has no approved products and generates no revenue from product sales [S2].
• Clinical development and regulatory approval processes for PIPE-791 and PIPE-307 are lengthy, costly, and uncertain, with risks including trial delays, failure to meet endpoints, and regulatory challenges [S2].
• Partnership with J&J provides access to R&D and commercialization capabilities for PIPE-307, but J&J controls further development decisions [S1][S2].
• Recent news coverage highlights clinical trial progress, including the Phase 2 MOONLIGHT-1 trial results for PIPE-307 and ongoing Phase 2 PROPEL-IPF trial for PIPE-791, as well as market and analyst commentary on Contineum's stock and pipeline [N1][N2][N3][N4][N5][N7][N8].